pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 1·1 min read
save

House set to vote on stopgap bill that could block White House plan to politicize NIH grants

Sep 1, 2026·read at STAT ↗RegulatoryPositive

Congressional leaders are preparing to vote on a Senate stopgap funding bill that would temporarily block the White House's proposal to place political appointees in charge of NIH research grants.

The House plans to use a fast-track procedure that requires a two-thirds majority, signaling that GOP leadership believes the Senate version will clear the chamber.

If the measure does not pass, lawmakers will have to wait until the Senate reconvenes on Sept. 14 to revisit the issue.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Will House delay Trump plan to politicize NIH grants?”

read at STAT ↗
614 words · retrieved Sep 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
CYCLE2Moderna, Inc.Ultragenyx Pharmaceutical Inc.
topics
Oncology2CardiologyHematologyRare DiseasemRNA Therapeutic

related stories

  • 3d agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Aug 31STAT+: Trump strikes nine more deals with drugmakers to lower pricesSTAT
  • Aug 31STAT+: Can a pregnancy hormone steer a cardiovascular treatment?STAT
  • Aug 31STAT+: After a rough stretch, mRNA gets a boost — at least for nowSTAT
  • Aug 31STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapySTAT